Sign in Subscribe
Medical equipment industry

CYTOGEN Corporation Reports 1994 Financial Results and Future Plans

Strategic Insights

— 2 min read

CYTOGEN Corporation has reported a decrease in operating expenses by 16% in 1994 and reaffirmed its commitment to reducing and controlling spending in 1995. The company's financial results for 1994, highlighted by a decrease in total revenues to $2.5 million compared to $10.4 million in 1993, are attributed to the absence of contract revenue from CytoRad, a subsidiary acquired by CYTOGEN in 1995. Despite the decrease in revenues, CYTOGEN has made significant progress in strategic initiatives, including the establishment of a co-marketing agreement with DuPont Merck Pharmaceutical Company for Samarium 153 EDTMP, a radiopharmaceutical drug for treating bone pain. The company has also submitted a Product License Application with the U.S. Food and Drug Administration (FDA) for ProstaScint, an imaging agent for prostate cancer.

Key Takeaways:

  • CYTOGEN reported a 16% decrease in operating expenses in 1994.
  • The company's total revenues decreased to $2.5 million in 1994 compared to $10.4 million in 1993.
  • The decrease in revenues is primarily due to the absence of contract revenue from CytoRad.
  • CYTOGEN established a co-marketing agreement with DuPont Merck Pharmaceutical Company for Samarium 153 EDTMP.
  • The company submitted a Product License Application with the FDA for ProstaScint.
  • CYTOGEN reacquired marketing rights for OncoScint CR/OV, an imaging agent for colorectal and ovarian cancers.
  • The company incurred one-time charges of $4.1 million in the fourth quarter of 1994.
  • CYTOGEN's cash and short-term investments decreased to $7.7 million as of December 31, 1994.
  • The company received upfront payments of $1.0 million from DuPont Merck and expect to receive additional payments of up to $2.9 million.
  • CYTOGEN plans to reduce its spending and focus on its highest priorities.

Statistics:

  • $2.5 million: CYTOGEN's total revenues in 1994.
  • $10.4 million: CYTOGEN's total revenues in 1993.
  • 16%: Decrease in operating expenses in 1994.
  • $4.1 million: One-time charges incurred by CYTOGEN in the fourth quarter of 1994.
  • $7.7 million: CYTOGEN's cash and short-term investments as of December 31, 1994.
  • $23.8 million: CYTOGEN's cash and short-term investments as of January 1, 1994.
  • $1.0 million: Upfront payment received by CYTOGEN from DuPont Merck.
  • $4.0 million: Payment received by CYTOGEN from DuPont Merck in the first quarter of 1995.
  • $1.3 million: Payment received by CYTOGEN from DuPont Merck in the first quarter of 1995.

Sources:

  • PRNewswire, February 16, 1995.
  • CYTOGEN Corporation, Press Release, February 16, 1995.
  • DuPont Merck Pharmaceutical Company, Press Release, January 20, 1995.

Read more